Last updated: September 17, 2026
Saxagliptin is a mature dipeptidyl peptidase-4 (DPP-4) inhibitor marketed primarily as Onglyza by AstraZeneca. Its commercial peak occurred before the rapid expansion of newer diabetes therapies, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. U.S. composition-of-matter exclusivity ended in 2022, and generic saxagliptin products subsequently entered the market. The franchise remains commercially relevant through combination products, established prescriber familiarity, and international sales, but its revenue trajectory is structurally negative.
What is saxagliptin and how is it marketed?
Saxagliptin is an oral DPP-4 inhibitor approved for adults with type 2 diabetes mellitus. It increases incretin activity and improves glycemic control by reducing the breakdown of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
The principal branded products are:
| Product |
Active ingredients |
Dosage form |
Commercial owner |
| Onglyza |
Saxagliptin |
2.5 mg and 5 mg tablets |
AstraZeneca |
| Kombiglyze XR |
Saxagliptin and metformin extended-release |
Extended-release tablets |
AstraZeneca |
| Qtern |
Saxagliptin and dapagliflozin |
Fixed-dose tablets |
AstraZeneca |
| Qternmet XR |
Saxagliptin, dapagliflozin and metformin extended-release |
Extended-release tablets |
AstraZeneca |
The FDA approved Onglyza in July 2009. Kombiglyze XR was approved in November 2010, Qtern in February 2017, and Qternmet XR in May 2019.[1-4]
Bristol Myers Squibb originally developed saxagliptin. AstraZeneca assumed global rights through its diabetes collaboration with Bristol Myers Squibb and later acquired Bristol Myers Squibb’s interest in the diabetes alliance. The transaction consolidated commercial control of Onglyza, Kombiglyze XR and related diabetes assets under AstraZeneca.[5]
How large is the saxagliptin market?
Saxagliptin competes in a crowded oral diabetes market that includes sitagliptin, linagliptin, alogliptin and several combination products. The DPP-4 class has generally lost share to SGLT2 inhibitors and GLP-1 receptor agonists because those newer classes have stronger cardiovascular, renal or weight-loss positioning in selected patients.
Key market pressures include:
- Loss of U.S. composition-of-matter exclusivity.
- Generic competition in saxagliptin monotherapy.
- Reduced use of DPP-4 inhibitors in patients prioritized for cardiovascular or renal risk reduction.
- Declining commercial importance of older branded diabetes products.
- Pricing pressure from payers and pharmacy benefit managers.
- Limited differentiation among DPP-4 inhibitors on glycemic efficacy.
Saxagliptin retains demand where physicians prioritize oral administration, low hypoglycemia risk, formulary access and long-standing clinical familiarity. Its market position is weaker in treatment pathways driven by obesity, heart failure, chronic kidney disease or atherosclerotic cardiovascular disease.
What is the financial trajectory of Onglyza and the saxagliptin franchise?
AstraZeneca’s disclosures show a long-term decline in the saxagliptin franchise after its mature commercial period. Onglyza generated peak annual sales at approximately the billion-dollar level before facing class competition and loss-of-exclusivity pressure. Sales then declined as newer therapies gained prescription volume and branded pricing weakened.
The financial trajectory can be summarized as follows:
| Period |
Commercial position |
Financial effect |
| 2009-2013 |
U.S. launch and rapid DPP-4 class adoption |
Strong growth from new prescriptions |
| 2014-2016 |
Mature branded product |
High revenue, but increasing competition from Januvia and other DPP-4 products |
| 2017-2019 |
Qtern expansion and continuing class pressure |
Combination-product growth did not reverse Onglyza erosion |
| 2020-2022 |
Pre- and post-exclusivity decline |
Lower volume, contracting pressure and preparation for generic entry |
| 2023 onward |
Generic saxagliptin availability |
Reduced branded pricing power and lower U.S. revenue potential |
AstraZeneca reported Onglyza and related product sales separately in earlier annual reports, but later financial reporting placed greater emphasis on the company’s newer growth platforms. The company’s diabetes portfolio increasingly centered on Farxiga, an SGLT2 inhibitor, rather than saxagliptin products.[5-8]
The central commercial distinction is between franchise revenue and product revenue. Qtern and Qternmet XR extended saxagliptin into combination therapy, but the larger economic opportunity in the portfolio shifted to dapagliflozin. AstraZeneca’s Farxiga franchise became a major growth driver, while saxagliptin products moved into a mature or declining category.
When did saxagliptin lose U.S. patent exclusivity?
The principal U.S. composition-of-matter patent covering saxagliptin expired in 2022, subject to applicable patent-term and pediatric adjustments reflected in FDA records. The core patent estate included U.S. Patent No. 6,395,767 and related patents directed to saxagliptin compounds and pharmaceutical use.[9]
A simplified U.S. exclusivity timeline is:
| Event |
Date |
| First U.S. approval of Onglyza |
July 31, 2009 |
| Core patent expiry period |
2022 |
| Generic ANDA litigation and regulatory activity |
Primarily 2010s to early 2020s |
| Generic market entry |
After core exclusivity ended |
| Current commercial position |
Mature branded and generic market |
The FDA granted Onglyza five-year new chemical entity exclusivity at approval. That period protected the active ingredient from certain abbreviated new drug applications but did not prevent all forms of competitive development. The product also received pediatric-related exclusivity associated with FDA requirements and labeling activity.[1,10]
What patents protect saxagliptin and its combination products?
The saxagliptin patent estate consisted of several layers rather than a single patent.
Core compound patents
Core compound patents covered saxagliptin and related chemical compounds. These patents created the main barrier to generic saxagliptin tablets and were the most commercially important rights in the estate.
Formulation patents
Formulation and dosage-form patents addressed tablet compositions, extended-release delivery and combination products. These rights were more relevant to Kombiglyze XR and Qternmet XR than to immediate-release Onglyza.
Extended-release formulations can create separate patent issues because a generic applicant may need to demonstrate bioequivalence to a modified-release product while avoiding formulation claims. These patents can delay or complicate generic substitution even after compound patents expire.
Method-of-use patents
Saxagliptin labeling covers glycemic control in adults with type 2 diabetes, including use as monotherapy and in combination with other antidiabetic agents. Method-of-use patents can support patent-listing and litigation positions, but their practical value depends on claim scope, labeling, enforceability and the ability of a generic applicant to use a “skinny label” that omits patented indications.
Combination-product patents
Kombiglyze XR patents cover combinations of saxagliptin with metformin and extended-release delivery. Qtern patents cover saxagliptin with dapagliflozin. Qternmet XR adds metformin to the saxagliptin-dapagliflozin combination.
Combination-product patents can preserve differentiated protection after a single-agent patent expires. Their commercial value is limited when physicians and payers can substitute separate generic components or when the combination lacks a meaningful reimbursement advantage.
What is the Orange Book status of saxagliptin?
The FDA Orange Book lists patents and exclusivity information for approved small-molecule drug products. Saxagliptin products are small molecules, so the relevant regulatory pathway is an abbreviated new drug application rather than a biosimilar application.[10]
The Orange Book analysis has three practical implications:
- Generic applicants assess listed patents when preparing ANDA certifications.
- A Paragraph IV certification can trigger patent litigation before approval.
- Listed formulation or method-of-use patents may remain relevant after the core compound patent has expired.
Orange Book status must be reviewed separately for Onglyza, Kombiglyze XR, Qtern and Qternmet XR because each product has a different active-ingredient combination, dosage form and patent profile.
Which companies challenged saxagliptin patents?
Generic drug manufacturers challenged AstraZeneca-related patents through ANDA filings and Paragraph IV certifications. Publicly reported patent disputes involved generic manufacturers seeking approval for saxagliptin or saxagliptin-containing products before the asserted patents expired.
The main competitive group included:
- Teva Pharmaceuticals.
- Mylan, now part of Viatris.
- Apotex.
- Aurobindo.
- Zydus.
- Other ANDA sponsors pursuing saxagliptin tablets or combination products.
The litigation pattern was consistent with mature small-molecule products: generic applicants challenged patent validity, enforceability or infringement, while the brand owner sought to preserve the remaining patent term. The commercial result was eventual generic entry after the core exclusivity period.
What is the FDA regulatory status of saxagliptin?
Onglyza, Kombiglyze XR, Qtern and Qternmet XR remain FDA-approved products. The FDA has also approved generic saxagliptin products through the ANDA pathway after the relevant patent and exclusivity barriers diminished.[1,10]
Saxagliptin carries important safety and clinical-positioning considerations. FDA labeling includes a warning regarding the risk of heart failure, particularly in patients with risk factors for heart failure or kidney disease.[1] The warning affects prescribing decisions because competing diabetes agents may offer more attractive cardiovascular or renal profiles for selected patients.
Saxagliptin is not a biologic. Biosimilar competition is therefore not applicable. The relevant erosion mechanism is generic substitution, not biosimilar interchangeability.
How strong is the saxagliptin patent estate?
The patent estate was commercially strong during the branded period because it protected a new active ingredient with a large diabetes market. Its current strength is materially lower.
| Patent-estate factor |
Assessment |
| Core compound protection |
Expired in the U.S. |
| Formulation protection |
Product-specific and potentially narrower |
| Combination-product protection |
Relevant for Qtern and Kombiglyze XR |
| Method-of-use protection |
Dependent on claim scope and label strategy |
| Generic blocking power |
Low for core saxagliptin; higher for selected combinations |
| International strength |
Country-specific and largely mature |
| Long-term revenue protection |
Limited |
The remaining estate can still support commercial differentiation for fixed-dose combinations, but it cannot recreate the economics of active-ingredient exclusivity.
What generic entry risks exist for AstraZeneca?
The highest generic-entry risk applies to saxagliptin monotherapy. Once generic tablets became available, payers could use formulary substitution, reference pricing and pharmacy-level substitution to reduce Onglyza volume.
Risk is lower but more complex for combination products because:
- Generic applicants may need to match extended-release characteristics.
- Combination products can have separate patent listings.
- Physicians may prescribe the individual components separately.
- Payers may favor lower-cost component substitution.
- Fixed-dose combinations can lose share if their price premium is not justified.
A likely generic-launch sequence is:
- Generic saxagliptin tablets gain approval and enter at discounted prices.
- Commercial insurers shift preferred status toward generics.
- Branded Onglyza volume contracts.
- Combination products face indirect competition from separate generic ingredients.
- AstraZeneca retains selected patients through brand familiarity, contracting or combination convenience.
How does saxagliptin compare with competing diabetes drugs?
| Drug or class |
Primary advantage |
Competitive effect on saxagliptin |
| Sitagliptin |
Established DPP-4 alternative and broad clinical familiarity |
Direct class competition |
| Linagliptin |
Convenient renal dosing profile |
Strong substitute in kidney disease |
| Alogliptin |
Low-cost DPP-4 option |
Price-based pressure |
| SGLT2 inhibitors |
Cardiovascular and renal outcome positioning |
Draws patients away from DPP-4 therapy |
| GLP-1 receptor agonists |
Greater glucose lowering and weight-loss benefits |
Reduces use in obesity-focused treatment |
| Metformin |
Low cost and guideline familiarity |
Limits saxagliptin use as early-line therapy |
Farxiga is strategically more important to AstraZeneca than saxagliptin because it participates in diabetes, heart failure and chronic kidney disease markets. This portfolio shift reduces the company’s incentive to defend saxagliptin through aggressive commercial investment.
What licensing deals shaped saxagliptin commercialization?
Bristol Myers Squibb and AstraZeneca formed a diabetes collaboration that included saxagliptin and other diabetes products. AstraZeneca later acquired Bristol Myers Squibb’s interest in the collaboration, consolidating ownership and commercialization rights.[5]
The deal structure mattered because it allowed saxagliptin to reach global markets through a large pharmaceutical commercial platform. It also placed lifecycle management, combination development and eventual post-exclusivity strategy under AstraZeneca’s control.
Key Takeaways
- Saxagliptin is a mature oral DPP-4 inhibitor marketed mainly through Onglyza and combination products.
- U.S. core patent protection ended in 2022.
- Generic saxagliptin is the principal threat to Onglyza revenue.
- Combination products retain narrower formulation and combination-patent protection.
- Qtern and Qternmet XR are strategically linked to dapagliflozin, but Farxiga has greater long-term commercial importance.
- SGLT2 inhibitors and GLP-1 receptor agonists have weakened the DPP-4 market.
- Saxagliptin is subject to generic, not biosimilar, competition.
- The franchise’s financial trajectory is declining, with limited prospects for a return to branded peak sales.
FAQs About Saxagliptin Market and Patent Strategy
Is saxagliptin still commercially viable after generic entry?
Yes, but mainly as a lower-cost generic or as part of selected fixed-dose combinations. Its branded growth potential is limited.
Does saxagliptin have cardiovascular benefits comparable to SGLT2 inhibitors?
No. Saxagliptin has not established the same cardiovascular and renal outcome positioning that supports several SGLT2 inhibitors.
Can generic manufacturers substitute saxagliptin for Onglyza?
Approved generic saxagliptin tablets may be pharmaceutically equivalent to the corresponding branded product, subject to state substitution rules, payer policies and product-specific approvals.
Are Qtern patents stronger than Onglyza patents?
Qtern may retain product-specific combination or formulation protection beyond the core saxagliptin patent term, but its practical strength depends on the listed claims, expiration dates, litigation outcomes and competition from separate generic components.
Is saxagliptin exposed to biosimilar competition?
No. Saxagliptin is a chemically synthesized small molecule. Its relevant competitors are generic drugs approved through the ANDA pathway.
References
-
U.S. Food and Drug Administration. (2009). Onglyza (saxagliptin) prescribing information.
-
U.S. Food and Drug Administration. (2010). Kombiglyze XR (saxagliptin and metformin hydrochloride extended-release) prescribing information.
-
U.S. Food and Drug Administration. (2017). Qtern (dapagliflozin and saxagliptin) prescribing information.
-
U.S. Food and Drug Administration. (2019). Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride extended-release) prescribing information.
-
AstraZeneca PLC. (2014). Annual report and Form 20-F 2014.
-
AstraZeneca PLC. (2018). Annual report and Form 20-F 2018.
-
AstraZeneca PLC. (2019). Annual report and Form 20-F 2019.
-
AstraZeneca PLC. (2020). Annual report and Form 20-F 2020.
-
United States Patent and Trademark Office. (2002). U.S. Patent No. 6,395,767: Beta-amino tetrahydroimidazo[1,2-a]pyrazine derivatives as dipeptidyl peptidase-IV inhibitors.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition.
